Atara Biotherapeutics is engaged in T-cell immunotherapy, utilizing its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co. has several T-cell immunotherapies in clinical development and is progressing multiple allogeneic chimeric antigen receptors T programs, which include: Tab-cel®, a T-cell immunotherapy for patients with Epstein-Barr virus, post-transplant lymphoproliferative disease, who have failed rituximab or rituximab plus chemotherapy, as well as other EBV diseases; and ATA188, a T-cell immunotherapy targeting EBV antigens for the treatment of multiple sclerosis. The ATRA stock yearly return is shown above.
The yearly return on the ATRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ATRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|